This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to ...

VANCOUVER, BC / ACCESS Newswire / November 4, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, ...

Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation TechnologyExpert consensus predicts integration of CTC testing into ...

POTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the ...

COPENHAGEN, DENMARK / ACCESS Newswire / November 3, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, ...

Voters and researchers head to Parliament to see how politicians are using evidenceThe public has made it clear that they expect MPs to look at the evidence when making decisions[1]. Following a ...

Dr. Naderi reveals how younger generations are embracing prejuvenation with collagen-boosting treatments and skincare to maintain a natural, youthful glow before aging signs appear. RESTON, VA / ...

LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first ...

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / ...

Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech / pharma companiesAddressing large and ...